Nurix Therapeutics, Inc. · NASDAQ:NRIX
Nurix Therapeutics — J.P. Morgan Healthcare Conference 2026
27 slides from Nurix Therapeutics's conference presentation, Jan 12, 2026
Slide 1: Protein Degraders to Outmatch Cancer and Autoimmune Disease
Protein Degraders to Outmatch Cancer and Autoimmune Disease J.P. Morgan Healthcare Conference January 12, 2026 Exhibit 99.1
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words “anticipa
Slide 3: Our Mission
3 OUR MISSION To establish degrader-based medicines at the forefront of patient care
Slide 4: Targeted Protein Degradation: Leading the Next Frontier in Drug Development
Targeted protein degradation (TPD) Leading the Next Frontier in Drug Development 4 Evolution of new therapeutic modalities AntibodiesSmall molecule inhibitors Nucleic acid-based therapies (Antisense, RNAi Gene Therapy, CRISPR) Targeted protein degraders
Slide 5: 2025: A Breakthrough Year Achieving Several Key Milestones
2025: A Breakthrough Year Achieving Several Key Milestones 5 Clinical Execution Excellence Initiated pivotal DAYBreak-201 Phase 2 study designed to support Accelerated Approval of bexobrutideg in relapsed/refractory CLL Robust results presented at ASH: 83% ORR and 22.1-month median PFS Secured
Slide 6: Nurix Is Advancing a Pipeline of Proprietary and Partnered Programs
Nurix Is Advancing a Pipeline of Proprietary and Partnered Programs in Oncology and Inflammation & Immunology 6 Program Target Modality Therapeutic area Discovery IND-Enabling Phase 1A Phase 1B/2 Pivotal Bexobrutideg (NX-5948) BTK Degrader B-cell malignancies Zelebrudomide (NX-2127) BTK-IKZF Degrade
Slide 7: Bexobrutideg – The First "deg" with a Potential Best-in-Class Profile
Bexobrutideg – The First “deg” with a Potential Best-in-Class Profile Novel MOA Against a Clinically and Commercially Proven Target 7 Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrates robust clinical activity in diff
Slide 8: Bexobrutideg – The First "deg" with a Potential Best-in-Class Profile
Bexobrutideg – The First “deg” with a Potential Best-in-Class Profile Novel MOA Against a Clinically and Commercially Proven Target 8 Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrates robust clinical activity in diff
Slide 9: Bexobrutideg – The First "deg" with a Potential Best-in-Class Profile
Bexobrutideg – The First “deg” with a Potential Best-in-Class Profile Novel MOA Against a Clinically and Commercially Proven Target 9 Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrates robust clinical activity in diff
Slide 10: Bexobrutideg – The First "deg" with a Potential Best-in-Class Profile
Bexobrutideg – The First “deg” with a Potential Best-in-Class Profile Novel MOA Against a Clinically and Commercially Proven Target 10 Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrates robust clinical activity in dif
Slide 11: Bexobrutideg – The First "deg" with a Potential Best-in-Class Profile
Bexobrutideg – The First “deg” with a Potential Best-in-Class Profile Novel MOA Against a Clinically and Commercially Proven Target 11 Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrates robust clinical activity in dif
Slide 12: Bexobrutideg – The First "deg" with a Potential Best-in-Class Profile
Bexobrutideg – The First “deg” with a Potential Best-in-Class Profile Novel MOA Against a Clinically and Commercially Proven Target 12 Exquisitely selective degrader of BTK Active against wildtype BTK and overcomes BTK inhibitor resistance mutations Demonstrates robust clinical activity in dif
Slide 13: Broad Clinical Activity Across Patients with BTK Mutations and CNS Involvement
Broad Clinical Activity Across Patients with BTK Mutations, High-Risk Molecular Features and/or CNS Involvement aWaterfall plot includes patients with measurable lymph node status (n=93); mutations were reported at VAF >5%; bPatients could have no mutations, a single mutation, or multiple mutations
Slide 14: Bexobrutideg Demonstrates Deep and Durable Responses in CLL
Bexobrutideg Demonstrates Deep and Durable Responses in CLL Updated Phase 1a results presented at ASH 2025 14 Robust Response Rate in Patients with a Median of 4 Prior Lines of Therapy Long-term Disease Control with a Median PFS of 22.1 Months Across All Doses Tested (50mg – 600mg, n=48) CLL respons
Slide 15: Bexobrutideg is Well Tolerated in Patients with Relapsed/Refractory CLL
Comparable AE profile for patients overall and at the 600 mg dose selected per Project Optimus Bexobrutideg is Well Tolerated in Patients with Relapsed/Refractory CLL Data cutoff: 19 Sep 2025aPurpura/contusion includes episodes of contusion or purpura; bAggregate of ‘neutrophil count decreased’ or ‘
Slide 16: Preliminary Efficacy in Phase 1b Randomized Cohort of 200 mg vs 600 mg
Preliminary efficacy in Phase 1b randomized cohort of 200 mg vs 600 mg Higher ORR and PFS Observed at 600 mg Dose Selected for Pivotal Trials Data cutoff: 19 Sep 2025aObjective response rate includes CR + nPR + PR + PR-L CI, confidence interval; ORR, objective response rate; PFS, progression-free su
Slide 17: Latest Bexobrutideg Data Supports a Best-in-Class Pivotal Trial Strategy
Latest Bexobrutideg Data Supports a Best-in-Class Pivotal Trial Strategy 17 Endpoint Bexobrutideg Pirtobrutinib (FDA full approval 12/3/2025) Objective Response Rate (ORR) 83.0% 65% (69% investigator) Median Duration of Response (DOR) 20.1 months 13.8 months (13.9 investigator) Median Progression-Fr
Slide 18: DAYBreak Pivotal Phase 2 Single-Arm Study
DAYBreak Pivotal Phase 2 Single-Arm Study Designed to Support Bexobrutideg Accelerated Approval 18 600 mg cleared for pivotal studies in R/R CLLFirst patient dosed in October 2025 Key Eligibility • R/R CLL/SLL • Triple- exposed (post-cBTKi, ncBTKi & BCL-2i) Response assessment every 8 weeks until we
Slide 19: DAYBreak Phase 3 Confirmatory Trial Positions Bexobrutideg for Full Approval
TR IA L D ES IG N DAYBreak Phase 3 Confirmatory Trial Positions Bexobrutideg for Full Approval 19 Stratified by high-risk genetic features and prior lines of therapy Note: Final design pending regulatory feedback r/r CLL, relapsed or refractory chronic lymphocytic leukemia; PFS, progression-free sur
Slide 20: NX-5948-203: Phase 1b/2 Combination Study in CLL
NX-5948-203: Phase 1b/2 Combination Study to Address Emerging Treatment Standards in CLL 20 CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; ORR, objective response rate; QD, once daily; RP2D, recommended Phase 2 dose Strategy provides potential path to 1L CLLCombination regimen o
Slide 21: Clinical Development Plan Addressing Large Segments of the CLL Market
Nurix Has a Clinical Development Plan Addressing Large Segments of the CLL Market as Both a Mono- and Combo- Therapy 21 ~19K treated in R/R CLL ~19K1L treated ~11K2L treated ~8K3L+ treated US Drug-Treated IncidenceDrug-Treated Incidence in Major Markets US, Canada, Europe, Japan, China ~60K treated
Slide 22: Unlocking Waves of Clinical Benefit and Value Creation
Unlocking Waves of Clinical Benefit and Value Creation 22 * Phase 2 single-arm study designed to support Accelerated Approval Pivotal DAYBreak CLL-201 trial initiated in October 2025; Confirmatory Phase 3 planned to start in 2026 Phase 1b/2 combination study planned to start in 2026 to enable pivota
Slide 23: Industry-Leading Wholly Owned and Partnered Degrader Portfolio in Inflammation and Autoimmune Diseases
Nurix’s Industry-Leading Wholly Owned and Partnered Degrader Portfolio in Inflammation and Autoimmune Diseases 1Patient estimate across key indications in U.S., EU5 and JP (2023); 2Annual sales across modalities (2023) Sources: GlobalData, Lumanity analysis, Evaluate Pharma, IQVIA Institute for Huma
Slide 24: Industry-Leading Wholly Owned and Partnered Degrader Portfolio in Inflammation and Autoimmune Diseases
Nurix’s Industry-Leading Wholly Owned and Partnered Degrader Portfolio in Inflammation and Autoimmune Diseases 24 BTK Bexobrutideg (wholly owned) New tablet formulation in Phase 1 SAD/MAD study B-cell & myeloid cell-driven inflammation STAT6 Type 2 inflammation NX-3911 (partnered with Sanofi) IND-en
Slide 25: 2026: Building the Future of Protein Degradation
2026: Building the Future of Protein Degradation 25 Enrollment of Pivotal Phase 2 trial – DAYBreak CLL-201 Initiation of bexobrutideg confirmatory Phase 3 study in r/r CLL – DAYBreak CLL-306 Initiation of bexobrutideg combination study in CLL Potential GS-6791 IRAK4 degrader Phase 1 results
Slide 26: Q&A
Q&A (NWuURIX
Slide 27: Abbreviations
Abbreviations • AD = Atopic dermatitis • BP = Bullous pemphigoid • COPD = Chronic obstructive pulmonary disease • CD = Crohn’s disease • CRwNP = Chronic rhinosinusitis with nasal polyps • CSU = Chronic spontaneous urticaria • CLE = Cutaneous lupus erythematosus • EoE = Eosinophilic esophagitis • wAI
Nurix Therapeutics — J.P. Morgan Healthcare Conference 2026 on 6ix